News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
131,513 Results
Type
Article (7615)
Company Profile (58)
Press Release (123837)
Multimedia
Podcasts (22)
Webinars (5)
Section
Business (38509)
Career Advice (89)
Deals (5998)
Drug Delivery (10)
Drug Development (23819)
Employer Resources (12)
FDA (3065)
Job Trends (3596)
News (69274)
Policy (4622)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (328)
Accelerated approval (12)
Adcomms (13)
Allergies (3)
Alliances (11305)
ALS (21)
Alzheimer's disease (164)
Antibody-drug conjugate (ADC) (252)
Approvals (3223)
Artificial intelligence (174)
Autoimmune disease (54)
Automation (5)
Bankruptcy (55)
Best Places to Work (3308)
BIOSECURE Act (1)
Biosimilars (89)
Biotechnology (50)
Bladder cancer (126)
Brain cancer (47)
Breast cancer (488)
Cancer (3515)
Cardiovascular disease (36)
Career advice (82)
Career pathing (5)
CAR-T (126)
CDC (3)
Cell therapy (266)
Cervical cancer (18)
Clinical research (21245)
Collaboration (683)
Company closure (2)
Compensation (215)
Complete response letters (10)
COVID-19 (352)
CRISPR (26)
C-suite (290)
Cystic fibrosis (8)
Data (2255)
Decentralized trials (1)
Denatured (4)
Depression (11)
Diabetes (38)
Diagnostics (1405)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (98)
Drug pricing (25)
Drug shortages (1)
Duchenne muscular dystrophy (27)
Earnings (13965)
Editorial (12)
Employer branding (2)
Employer resources (13)
Events (24918)
Executive appointments (315)
FDA (3907)
Fibrodysplasia Ossificans Progressiva (3)
Frontotemporal dementia (2)
Funding (329)
Gene editing (44)
Generative AI (17)
Gene therapy (91)
GLP-1 (127)
Government (487)
Guidances (87)
Healthcare (4075)
HIV (8)
Huntington's disease (3)
IgA nephropathy (17)
Immunology and inflammation (70)
Immuno-oncology (60)
Indications (55)
Infectious disease (391)
Inflammatory bowel disease (35)
Inflation Reduction Act (3)
Influenza (15)
Intellectual property (57)
Interviews (12)
IPO (2993)
IRA (8)
Job creations (484)
Job search strategy (70)
JPM (25)
Kidney cancer (17)
Labor market (9)
Layoffs (140)
Leadership (6)
Legal (478)
Liver cancer (48)
Longevity (1)
Lung cancer (522)
Lymphoma (225)
Machine learning (14)
Management (3)
Manufacturing (135)
MASH (6)
Medical device (880)
Medtech (885)
Mergers & acquisitions (3264)
Metabolic disorders (106)
Multiple sclerosis (15)
NASH (1)
Neurodegenerative disease (30)
Neuropsychiatric disorders (9)
Neuroscience (322)
NextGen: Class of 2026 (956)
Non-profit (507)
Now hiring (18)
Obesity (60)
Opinion (38)
Ovarian cancer (132)
Pain (27)
Pancreatic cancer (168)
Parkinson's disease (31)
Partnered (1)
Patents (93)
Patient recruitment (160)
Peanut (2)
People (13516)
Pharmaceutical (12)
Pharmacy benefit managers (3)
Phase 1 (8022)
Phase 2 (8881)
Phase 3 (6847)
Pipeline (1684)
Policy (33)
Postmarket research (472)
Preclinical (2537)
Press Release (2)
Prostate cancer (170)
Psychedelics (4)
Radiopharmaceuticals (187)
Rare diseases (144)
Real estate (753)
Recruiting (5)
Regulatory (4775)
Reports (8)
Research institute (696)
Resumes & cover letters (11)
RNA editing (2)
RSV (10)
Schizophrenia (37)
Series A (65)
Series B (30)
Service/supplier (1)
Sickle cell disease (37)
Special edition (3)
Spinal muscular atrophy (16)
Sponsored (6)
Startups (769)
State (1)
Stomach cancer (12)
Supply chain (12)
Tariffs (8)
The Weekly (18)
Vaccines (189)
Venture capital (34)
Weight loss (25)
Women's health (6)
Date
Today (30)
Last 7 days (154)
Last 30 days (565)
Last 365 days (8385)
2026 (957)
2025 (8415)
2024 (9473)
2023 (10648)
2022 (13123)
2021 (13183)
2020 (10979)
2019 (8608)
2018 (6348)
2017 (7129)
2016 (6293)
2015 (6974)
2014 (4544)
2013 (3097)
2012 (3345)
2011 (3336)
2010 (3039)
Location
Africa (88)
Alabama (19)
Alaska (1)
Arizona (25)
Arkansas (2)
Asia (11416)
Australia (1544)
California (3143)
Canada (707)
China (597)
Colorado (82)
Connecticut (129)
Delaware (240)
Europe (20786)
Florida (411)
Georgia (12)
Idaho (6)
Illinois (308)
India (18)
Indiana (100)
Iowa (9)
Japan (208)
Kansas (10)
Kentucky (13)
Maine (4)
Maryland (337)
Massachusetts (2487)
Michigan (27)
Minnesota (111)
Missouri (12)
Montana (8)
Nebraska (2)
Nevada (10)
New Hampshire (10)
New Jersey (891)
New Mexico (3)
New York (746)
North Carolina (237)
Northern California (1665)
Ohio (66)
Oklahoma (1)
Oregon (5)
Pennsylvania (464)
Puerto Rico (3)
Rhode Island (6)
South America (117)
South Carolina (3)
Southern California (1237)
Tennessee (36)
Texas (540)
United States (10583)
Utah (75)
Virginia (26)
Washington D.C. (9)
Washington State (293)
Wisconsin (35)
131,513 Results for "mural oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
December 8, 2025
·
6 min read
Press Releases
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
November 27, 2025
·
6 min read
Press Releases
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
August 5, 2025
·
11 min read
Press Releases
Mural Oncology Announces Plans to Explore Strategic Alternatives
April 15, 2025
·
11 min read
Press Releases
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
August 21, 2025
·
119 min read
Business
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
Mural Oncology plc announced financial results for the first quarter of 2024 and provided a business update.
May 14, 2024
·
12 min read
Genetown
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Mural Oncology plc (Nasdaq: MURA) today announced an upcoming poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting taking place May 31-June 4 in Chicago.
April 24, 2024
·
2 min read
Press Releases
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
January 10, 2025
·
10 min read
Press Releases
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 18, 2025
·
1 min read
Business
Mural Oncology to Host Investor Webcast on October 17
Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023 (Mural Oncology), will hold an investor webcast during which members of Mural Oncology’s designated management team will provide an overview of the company, its pipeline and strategy.
October 10, 2023
·
3 min read
1 of 13,152
Next
